+44-330-822-4832
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Review Article
Interstitial Lung Disease Induced by Targeted Therapy for Non-Small Cell Lung Cancer: A Review of Diagnosis, Workup, and Management
Yuh-Min Chen2,3,4* and Yung-Hung Luo 1,2,31Chest Medicine Division of Medicine Department, Fenglin branch, Taipei Veterans General Hospital, Taiwan
2School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan
3Department of Chest Medicine, Taipei Veterans General Hospital, Taiwan
4Taipei Cancer Center, College of Medical Science and Technology, Taipei Medical University, Taiwan, ROC
- *Corresponding Author:
- Yuh-Min Chen
Department of Chest Medicine
Taipei Veterans General Hospital, 201
Sec. 2, Shih-pai Road, Taipei 112, Taiwan, ROC
Tel: 886-2-28763466
Fax: 886-2-28763466
E-mail: ymchen@vghtpe.gov.tw
Received date: March 02, 2014; Accepted date: April 24, 2014; Published date: April 26, 2014
Citation:Chen YM, Luo YH (2015) Interstitial Lung Disease Induced by Targeted Therapy for Non-Small Cell Lung Cancer: A Review of Diagnosis, Workup, and Management. J Palliat Care Med 5:204. doi:10.4172/2165-7386.1000204
Copyright: ©2015 Chen YM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Targeted therapies are being increasingly used for cancer treatments and had been proven to improve clinical outcomes. Although targeted therapies demonstrate survival benefit in particular patient populations, they may also increase the frequency of treatment-related toxicities and morbidity. The pulmonary toxicities, especially drug induced-interstitial lung disease (ILD), have emerged as critical adverse drug reactions which are potentially fatal.The main managment of targeted therapy-induced ILD includes drug discontinuation and corticosteroid therapy, but no standard guideline for the treatment of targeted therapy-induced ILD was established. Clinical physicians must cautiously weigh the benefits and risks of targeted therapies causing ILD in order to provide optimal treatments and favorable outcomes. Relevant clinical information regarding management of targeted therapy-induced ILD was reviewed in this article.
